Cours suspendu

Communiqués Revance Therapeutics, Inc.

Actions

RVNC

US7613301099

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 05/02/2025			Varia. 5j.	Varia. 1 janv.
3,650 ^USD	+0,27%		-.--%	-

20/08	Revance et Teoxane annoncent l'approbation par la FDA de RHA Redensity Eye pour le comblement des cernes	CI
17/08	Revance annonce la nomination de Janelle Wichmann au poste de directrice du marketing pour la division Skincare	CI

Communiqués

19/02/25	Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information	BU
18/02/25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC	PR
14/02/25	Revance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC	PR
13/02/25	Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC	PR
11/02/25	March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC	PR
10/02/25	The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Revance Therapeutics, Inc.(RVNC) Shareholders	PR
07/02/25	Crown Laboratories Completes Acquisition of Revance Therapeutics	BU
07/02/25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNC	PR
06/02/25	Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics	PR
06/02/25	The Gross Law Firm Notifies Shareholders of Revance Therapeutics, Inc.(RVNC) of a Class Action Lawsuit and an Upcoming Deadline	PR
05/02/25	Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer	PR
04/02/25	Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC	PR
03/02/25	Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline	AQ
03/02/25	Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC	PR
31/01/25	Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline	PR
31/01/25	Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNC	PR
30/01/25	The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC	PR
28/01/25	Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC	PR
27/01/25	Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More	PR
24/01/25	Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More	PR
23/01/25	Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC	PR
21/01/25	Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer	BU
21/01/25	Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer	PR
21/01/25	Shareholders of Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC	PR
20/01/25	Investors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC	PR